Safety, Tolerability, and Pharmacokinetics of Mevidalen (LY3154207), a Centrally Acting Dopamine D1 Receptor–Positive Allosteric Modulator, in Patients With Parkinson Disease

Autor: Paul A. Ardayfio, Max Tsai, Kevin Biglan, Melissa Pugh, Kjell A. Svensson, Darren Wilbraham, William Kielbasa

Publikováno v: Clinical Pharmacology in Drug Development. 11:324-332

Mevidalen (LY3154207) is a positive allosteric modulator of the dopamine D1 receptor that enhances the affinity of dopamine for the D1 receptor. The safety, tolerability, motor effects, and pharmacokinetics of mevidalen were studied in patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0756aada807d2ec9a96790887908870c
https://doi.org/10.1002/cpdd.1039

Safety, Tolerability, and Pharmacokinetics of Lasmiditan in Healthy Japanese and Caucasian Subjects

Autor: Darren Wilbraham, Go Takaichi, Mika Komori, Hanaka Mimura, Max Tsai, Akichika Ozeki

Publikováno v: Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 51:119-127

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cda8a9e2d30b4e37f060644b02187574
https://doi.org/10.3999/jscpt.51.119

Abuse Potential of Lasmiditan: A Phase 1 Randomized, Placebo‐ and Alprazolam‐Controlled Crossover Study

Autor: Edward M. Sellers, Li Shen Loo, Erin G Doty, Darren Wilbraham, Paul Berg, Max Tsai, Emily Liffick

Publikováno v: Journal of Clinical Pharmacology

Lasmiditan is a centrally penetrant, highly selective 5‐hydroxytryptamine (serotonin) receptor 1F (5HT1F) agonist under development as a novel therapy for acute treatment of migraine. A phase 1 randomized, placebo‐ and positive‐controlled cross

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8760e4485c07f9efd1185d9fa84470ea
http://europepmc.org/articles/PMC7078915

Effects of lasmiditan on simulated driving performance: Results of two randomized, blinded, crossover studies with placebo and active controls

Autor: Erin G Doty, Darren Wilbraham, Gary G. Kay, Max Tsai, Eric M. Pearlman, Ellen B. Dennehy, Paul Berg

Publikováno v: Human Psychopharmacology

Objective To evaluate the impact of lasmiditan, an oral, centrally‐penetrant, selective serotonin 1F (5‐HT1F) receptor agonist developed for the acute treatment of migraine, on simulated driving. Methods Healthy adult volunteers enrolled in two r

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::694c13bb7c9a54d75d061e9f2b36bf01
https://doi.org/10.1002/hup.2732

Pharmacokinetics, Pharmacodynamics, Tolerability, and Food Effect of Cenerimod, a Selective S1P1 Receptor Modulator in Healthy Subjects

Autor: Darren Wilbraham, Daniela Baldoni, Maribel Reyes, Pierre-Eric Juif, Andrea Vaclavkova, Jasper Dingemanse, Matthias Hoch, Salvatore Febbraro

Publikováno v: International Journal of Molecular Sciences, Vol 18, Iss 12, p 2636 (2017)
International Journal of Molecular Sciences; Volume 18; Issue 12; Pages: 2636

The pharmacokinetics, pharmacodynamics, tolerability, and food effect of cenerimod, a potent sphingosine-1-phosphate subtype 1 receptor modulator, were investigated in three sub-studies. Two double-blind, placebo-controlled, randomised studies in hea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0c4f4eb091bcb561bf0119f4cd4dd0f
https://www.mdpi.com/1422-0067/18/12/2636